Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Thaker, 2013, IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice, Gastroenterology, 145, 416, 10.1053/j.gastro.2013.05.002
Ferdinande, 2012, Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer, Br J Cancer, 106, 141, 10.1038/bjc.2011.513
Ciorba, 2013, Indoleamine 2,3 dioxygenase in intestinal disease, Curr Opin Gastroenterol, 29, 146, 10.1097/MOG.0b013e32835c9cb3
Beaugerie, 2015, Cancers complicating inflammatory bowel disease, N Engl J Med, 372, 1441, 10.1056/NEJMra1403718
Prendergast, 2014, Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer, Cancer Immunol Immunother, 63, 721, 10.1007/s00262-014-1549-4
Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210
Xiang, 2013, Colorectal cancer immunotherapy, Discov Med, 15, 301
Terzic, 2010, Inflammation and colon cancer, Gastroenterology, 138, 2101, 10.1053/j.gastro.2010.01.058
Ullman, 2011, Intestinal inflammation and cancer, Gastroenterology, 140, 1807, 10.1053/j.gastro.2011.01.057
Eaden, 2001, The risk of colorectal cancer in ulcerative colitis: a meta-analysis, Gut, 48, 526, 10.1136/gut.48.4.526
2009
Low, 2014, Recent advancement in understanding colitis-associated tumorigenesis, Inflamm Bowel Dis, 20, 2115, 10.1097/MIB.0000000000000094
Waldner, 2015, Mechanisms of immune signaling in colitis-associated cancer, Cell Mol Gastroenterol Hepatol, 1, 6, 10.1016/j.jcmgh.2014.11.006
He, 1998, Identification of c-MYC as a target of the APC pathway, Science, 281, 1509, 10.1126/science.281.5382.1509
Coca, 1997, The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma, Cancer, 79, 2320, 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P
Pages, 2005, Effector memory T cells, early metastasis, and survival in colorectal cancer, N Engl J Med, 353, 2654, 10.1056/NEJMoa051424
Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139
Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat Immunol, 3, 991, 10.1038/ni1102-991
Nan, 2015, Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants, JAMA, 313, 1133, 10.1001/jama.2015.1815
Velayos, 2006, Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study, Gastroenterology, 130, 1941, 10.1053/j.gastro.2006.03.028
Popivanova, 2008, Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis, J Clin Invest, 118, 560
Wang, 2014, Myeloid-derived suppressor cells link inflammation to cancer, Oncoimmunology, 3, e28581, 10.4161/onci.28581
Katoh, 2013, CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis, Cancer Cell, 24, 631, 10.1016/j.ccr.2013.10.009
Kanterman, 2014, Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes, Cancer Res, 74, 6022, 10.1158/0008-5472.CAN-14-0657
Postow, 2012, Immunologic correlates of the abscopal effect in a patient with melanoma, N Engl J Med, 366, 925, 10.1056/NEJMoa1112824
Lob, 2009, Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?, Nat Rev Cancer, 9, 445, 10.1038/nrc2639
Platten, 2014, Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors, Front Immunol, 5, 673
Peters, 1991, Tryptophan nutrition and metabolism: an overview, Adv Exp Med Biol, 294, 345, 10.1007/978-1-4684-5952-4_32
Austin, 2015, Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy, Drug Discov Today, 20, 609, 10.1016/j.drudis.2014.11.007
Ball, 2014, Tryptophan-catabolizing enzymes—party of three, Front Immunol, 5, 485, 10.3389/fimmu.2014.00485
Opitz, 2011, An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor, Nature, 478, 197, 10.1038/nature10491
Pilotte, 2012, Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase, Proc Natl Acad Sci U S A, 109, 2497, 10.1073/pnas.1113873109
Platten, 2012, Tryptophan catabolism in cancer: beyond ido and tryptophan depletion, Cancer Res, 72, 5435, 10.1158/0008-5472.CAN-12-0569
Munn, 1998, Prevention of allogeneic fetal rejection by tryptophan catabolism, Science, 281, 1191, 10.1126/science.281.5380.1191
Munn, 1999, Inhibition of T cell proliferation by macrophage tryptophan catabolism, J Exp Med, 189, 1363, 10.1084/jem.189.9.1363
Munn, 2007, Indoleamine 2,3-dioxygenase and tumor-induced tolerance, J Clin Invest, 117, 1147, 10.1172/JCI31178
Fougeray, 2012, Tryptophan depletion and the kinase GCN2 mediate IFN-gamma-induced autophagy, J Immunol, 189, 2954, 10.4049/jimmunol.1201214
Metz, 2012, IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan, Oncoimmunology, 1, 1460, 10.4161/onci.21716
Mezrich, 2010, An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells, J Immunol, 185, 3190, 10.4049/jimmunol.0903670
Nguyen, 2010, Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism, Proc Natl Acad Sci U S A, 107, 19961, 10.1073/pnas.1014465107
DiNatale, 2010, Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling, Toxicol Sci, 115, 89, 10.1093/toxsci/kfq024
Pallotta, 2011, Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells, Nat Immunol, 12, 870, 10.1038/ni.2077
Zaher, 2011, 3-Hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival, Invest Ophthalmol Vis Sci, 52, 2640, 10.1167/iovs.10-5793
Romani, 2007, Controlling pathogenic inflammation to fungi, Expert Rev Anti Infect Ther, 5, 1007, 10.1586/14787210.5.6.1007
Cobbold, 2009, Infectious tolerance via the consumption of essential amino acids and mTOR signaling, Proc Natl Acad Sci U S A, 106, 12055, 10.1073/pnas.0903919106
Howie, 2014, Nutrient sensing via mTOR in T cells maintains a tolerogenic microenvironment, Front Immunol, 5, 409, 10.3389/fimmu.2014.00409
Pallotta, 2014, AhR-mediated, non-genomic modulation of IDO1 function, Front Immunol, 5, 497, 10.3389/fimmu.2014.00497
Bessede, 2014, Aryl hydrocarbon receptor control of a disease tolerance defence pathway, Nature, 511, 184, 10.1038/nature13323
Lee, 2014, IDO1 and IDO2 non-synonymous gene variants: correlation with Crohn's disease risk and clinical phenotype, PLoS One, 9, e115848, 10.1371/journal.pone.0115848
Gurtner, 2003, Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice, Gastroenterology, 125, 1762, 10.1053/j.gastro.2003.08.031
Matteoli, 2010, Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction, Gut, 59, 595, 10.1136/gut.2009.185108
Ciorba, 2010, Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis, J Immunol, 184, 3907, 10.4049/jimmunol.0900291
Gupta, 2012, Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity, Inflamm Bowel Dis, 18, 1214, 10.1002/ibd.21849
Kraus, 2009, Inflammation and colorectal cancer, Curr Opin Pharmacol, 9, 405, 10.1016/j.coph.2009.06.006
Zou, 2005, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat Rev Cancer, 5, 263, 10.1038/nrc1586
Friberg, 2002, Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection, Int J Cancer, 101, 151, 10.1002/ijc.10645
Munn, 2002, Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase, Science, 297, 1867, 10.1126/science.1073514
von Bergwelt-Baildon, 2006, CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition, Blood, 108, 228, 10.1182/blood-2005-08-3507
Watkins, 2011, FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer, J Clin Invest, 121, 1361, 10.1172/JCI44325
Curiel, 2004, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, 10, 942, 10.1038/nm1093
Grohmann, 2002, CTLA-4-Ig regulates tryptophan catabolism in vivo, Nat Immunol, 3, 1097, 10.1038/ni846
Uyttenhove, 2003, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nat Med, 9, 1269, 10.1038/nm934
Muller, 2005, Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy, Nat Med, 11, 312, 10.1038/nm1196
Hou, 2007, Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses, Cancer Res, 67, 792, 10.1158/0008-5472.CAN-06-2925
Theate, 2015, Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues, Cancer Immunol Res, 3, 161, 10.1158/2326-6066.CIR-14-0137
Prendergast, 2008, Immune escape as a fundamental trait of cancer: focus on IDO, Oncogene, 27, 3889, 10.1038/onc.2008.35
Liu, 2010, Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity, Blood, 115, 3520, 10.1182/blood-2009-09-246124
Walczak, 2011, Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells, Scand J Gastroenterol, 46, 903, 10.3109/00365521.2011.579159
Engin, 2015, Helicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancer, World J Gastroenterol, 21, 3636, 10.3748/wjg.v21.i12.3636
Brandacher, 2006, Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells, Clin Cancer Res, 12, 1144, 10.1158/1078-0432.CCR-05-1966
Gao, 2009, The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer, J Transl Med, 7, 71, 10.1186/1479-5876-7-71
Ogawa, 2012, Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase, Cancer Sci, 103, 951, 10.1111/j.1349-7006.2012.02237.x
Takahashi, 2004, Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents, Cancer Sci, 95, 475, 10.1111/j.1349-7006.2004.tb03235.x
Smith, 2012, IDO is a nodal pathogenic driver of lung cancer and metastasis development, Cancer Discov, 2, 722, 10.1158/2159-8290.CD-12-0014
Lob, 2009, IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism, Cancer Immunol Immunother, 58, 153, 10.1007/s00262-008-0513-6
Flatmark, 2004, Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice, Eur J Cancer, 40, 1593, 10.1016/j.ejca.2004.02.023
Ahmed, 2013, Epigenetic and genetic features of 24 colon cancer cell lines, Oncogenesis, 2, e71, 10.1038/oncsis.2013.35
Smith, 2002, Mutations in APC, Kirsten-ras, and p53–alternative genetic pathways to colorectal cancer, Proc Natl Acad Sci U S A, 99, 9433, 10.1073/pnas.122612899
Wong, 2013, Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment, Oncogenesis, 2, e59, 10.1038/oncsis.2013.17
Chon, 1996, Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene, J Biol Chem, 271, 17247, 10.1074/jbc.271.29.17247
Litzenburger, 2014, Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR, Oncotarget, 5, 1038, 10.18632/oncotarget.1637
Ciorba, 2012, A gastroenterologist's guide to probiotics, Clin Gastroenterol Hepatol, 10, 960, 10.1016/j.cgh.2012.03.024
Arthur, 2014, Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer, Nat Commun, 5, 4724, 10.1038/ncomms5724
Wells, 2011, Epithelial crosstalk at the microbiota-mucosal interface, Proc Natl Acad Sci U S A, 108, 4607, 10.1073/pnas.1000092107
Zelante, 2013, Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22, Immunity, 39, 372, 10.1016/j.immuni.2013.08.003
Sommariva, 2011, TLR9 agonists oppositely modulate DNA repair genes in tumor versus immune cells and enhance chemotherapy effects, Cancer Res, 71, 6382, 10.1158/0008-5472.CAN-11-1285
Fallarino, 2015, LPS-conditioned dendritic cells confer endotoxin tolerance contingent on tryptophan catabolism, Immunobiology, 220, 315, 10.1016/j.imbio.2014.09.017
Hoshi, 2014, Blockade of indoleamine 2,3-dioxygenase reduces mortality from peritonitis and sepsis in mice by regulating functions of CD11b+ peritoneal cells, Infect Immun, 82, 4487, 10.1128/IAI.02113-14
Eiro, 2012, Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer, J Clin Immunol, 32, 848, 10.1007/s10875-012-9666-3
Iida, 2013, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment, Science, 342, 967, 10.1126/science.1240527
Furi, 2013, Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects, World J Gastroenterol, 19, 4119, 10.3748/wjg.v19.i26.4119
Ito, 2015, Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumor effects of a TLR7 agonist in an established cancer model, Immunology, 144, 621, 10.1111/imm.12413
Sommariva, 2012, Modulation of DNA repair genes induced by TLR9 agonists: a strategy to eliminate “altered” cells?, Oncoimmunology, 1, 258, 10.4161/onci.1.2.18343
Nugent, 2014, Altered tissue metabolites correlate with microbial dysbiosis in colorectal adenomas, J Proteome Res, 13, 1921, 10.1021/pr4009783
Chen, 2012, Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer, PLoS One, 7, e39743, 10.1371/journal.pone.0039743
Weir, 2013, Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults, PLoS One, 8, e70803, 10.1371/journal.pone.0070803
Raman, 2013, Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer, Gut Microbes, 4, 181, 10.4161/gmic.23919
He, 2013, Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells, Life Sci, 93, 509, 10.1016/j.lfs.2013.07.028
Wong, 2006, Colonic health: fermentation and short chain fatty acids, J Clin Gastroenterol, 40, 235, 10.1097/00004836-200603000-00015
Jiang, 2010, Sodium butyrate down-regulation of indoleamine 2,3-dioxygenase at the transcriptional and post-transcriptional levels, Int J Biochem Cell Biol, 42, 1840, 10.1016/j.biocel.2010.07.020
Singh, 2014, Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis, Immunity, 40, 128, 10.1016/j.immuni.2013.12.007
Wu, 2013, Dysbiosis signature of fecal microbiota in colorectal cancer patients, Microb Ecol, 66, 462, 10.1007/s00248-013-0245-9
Kawajiri, 2009, Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands, Proc Natl Acad Sci U S A, 106, 13481, 10.1073/pnas.0902132106
Biedermann, 2015, The intestinal microbiota: its role in health and disease, Eur J Pediatr, 174, 151, 10.1007/s00431-014-2476-2
Murray, 2014, Aryl hydrocarbon receptor ligands in cancer: friend and foe, Nat Rev Cancer, 14, 801, 10.1038/nrc3846
Andersson, 2002, A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors, Proc Natl Acad Sci U S A, 99, 9990, 10.1073/pnas.152706299
Gramatzki, 2009, Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells, Oncogene, 28, 2593, 10.1038/onc.2009.104
Bertazzi, 2001, Health effects of dioxin exposure: a 20-year mortality study, Am J Epidemiol, 153, 1031, 10.1093/aje/153.11.1031
Xie, 2012, Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation, Am J Physiol Gastrointest Liver Physiol, 302, G1006, 10.1152/ajpgi.00427.2011
Safe, 2013, Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target, Toxicol Sci, 135, 1, 10.1093/toxsci/kft128
Garten, 2009, Nampt: linking NAD biology, metabolism and cancer, Trends Endocrinol Metab, 20, 130, 10.1016/j.tem.2008.10.004
Sahm, 2013, The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress, Cancer Res, 73, 3225, 10.1158/0008-5472.CAN-12-3831
Xiao, 2013, Role of MUC20 overexpression as a predictor of recurrence and poor outcome in colorectal cancer, J Transl Med, 11, 151, 10.1186/1479-5876-11-151
Kawamori, 2003, Enhancement of colon carcinogenesis by prostaglandin E2 administration, Carcinogenesis, 24, 985, 10.1093/carcin/bgg033
Markowitz, 2009, Molecular origins of cancer: molecular basis of colorectal cancer, N Engl J Med, 361, 2449, 10.1056/NEJMra0804588
Cianchi, 2003, Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis, Am J Pathol, 162, 793, 10.1016/S0002-9440(10)63876-X
Takahashi, 2000, Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis, Carcinogenesis, 21, 1319, 10.1093/carcin/21.7.1319
Hao, 2001, Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients, Cancer Res, 61, 419
Mei, 2000, Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells, FASEB J, 14, 1188, 10.1096/fasebj.14.9.1188
Zhu, 2012, iNOS signaling interacts with COX-2 pathway in colonic fibroblasts, Exp Cell Res, 318, 2116, 10.1016/j.yexcr.2012.05.027
Marnett, 2000, Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase, J Biol Chem, 275, 13427, 10.1074/jbc.275.18.13427
Salvemini, 1993, Nitric oxide activates cyclooxygenase enzymes, Proc Natl Acad Sci U S A, 90, 7240, 10.1073/pnas.90.15.7240
Salvemini, 1999, Protective effects of a superoxide dismutase mimetic and peroxynitrite decomposition catalysts in endotoxin-induced intestinal damage, Br J Pharmacol, 127, 685, 10.1038/sj.bjp.0702604
Gobel, 2014, Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity, Cell Death Dis, 5, e1568, 10.1038/cddis.2014.531
Lee, 2009, The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells, J Immunother, 32, 22, 10.1097/CJI.0b013e31818ac2f7
Iachininoto, 2013, Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells, Molecules, 18, 10132, 10.3390/molecules180910132
Zhang, 2013, The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2,3-dioxygenase in gastric cancer, Dig Dis Sci, 58, 3494, 10.1007/s10620-013-2837-0
Yoshii, 2012, Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach, Br J Cancer, 106, 1668, 10.1038/bjc.2012.141
Zhang, 2011, Immunoactivative role of indoleamine 2,3dioxygenase in gastric cancer cells in vitro, Mol Med Rep, 4, 169
Witkiewicz, 2008, Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection, J Am Coll Surg, 206, 849, 10.1016/j.jamcollsurg.2007.12.014
Witkiewicz, 2009, Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target, J Am Coll Surg, 208, 781, 10.1016/j.jamcollsurg.2008.12.018
Koblish, 2010, Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors, Mol Cancer Ther, 9, 489, 10.1158/1535-7163.MCT-09-0628
Liu, 2009, Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas, Virchows Arch, 455, 441, 10.1007/s00428-009-0846-3
Zhang, 2011, Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma, Clin Dev Immunol, 2011, 384726, 10.1155/2011/384726
Balachandran, 2011, Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido, Nat Med, 17, 1094, 10.1038/nm.2438
Metz, 2007, Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan, Cancer Res, 67, 7082, 10.1158/0008-5472.CAN-07-1872
Metz, 2014, IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation, Int Immunol, 26, 357, 10.1093/intimm/dxt073
Newton, 2012, Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.2500
Beatty, 2013, Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.3025
Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088
Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095
Puccetti, 2015, Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers, PLoS One, 10, e0122046, 10.1371/journal.pone.0122046
Zheng, 2006, Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference, J Immunol, 177, 5639, 10.4049/jimmunol.177.8.5639
Zheng, 2013, Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model, Int J Cancer, 132, 967, 10.1002/ijc.27710
Maleki Vareki, 2014, Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin, Oncotarget, 5, 2778, 10.18632/oncotarget.1916